# Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

> **NCT06564142** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Alpine Immune Sciences Inc, A Subsidiary of Vertex** · enrollment: 605 (actual)

## Conditions studied

- Immunoglobulin A Nephropathy

## Interventions

- **DRUG:** Povetacicept
- **DRUG:** Placebo (matched to Povetacicept)

## Key facts

- **NCT ID:** NCT06564142
- **Lead sponsor:** Alpine Immune Sciences Inc, A Subsidiary of Vertex
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-30
- **Primary completion:** 2028-01-30
- **Final completion:** 2028-01-30
- **Target enrollment:** 605 (ACTUAL)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06564142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06564142, "Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT06564142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*